WallStSmart

DexCom Inc (DXCM)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 342% more annual revenue ($20.63B vs $4.66B). DXCM leads profitability with a 17.9% profit margin vs 10.1%. DXCM appears more attractively valued with a PEG of 1.46. DXCM earns a higher WallStSmart Score of 72/100 (B).

DXCM

Strong Buy

72

out of 100

Grade: B

Growth: 8.0Profit: 9.0Value: 10.0Quality: 7.5
Piotroski: 5/9Altman Z: 2.56

GEHC

Buy

60

out of 100

Grade: C+

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DXCMUndervalued (+30.3%)

Margin of Safety

+30.3%

Fair Value

$97.81

Current Price

$66.84

$30.97 discount

UndervaluedFair: $97.81Overvalued
GEHCSignificantly Overvalued (-156.0%)

Margin of Safety

-156.0%

Fair Value

$30.94

Current Price

$72.20

$41.26 premium

UndervaluedFair: $30.94Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DXCM3 strengths · Avg: 9.3/10
Return on EquityProfitability
34.5%10/10

Every $100 of equity generates 35 in profit

EPS GrowthGrowth
78.0%10/10

Earnings expanding 78.0% YoY

Operating MarginProfitability
25.6%8/10

Strong operational efficiency at 25.6%

GEHC2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Areas to Watch

DXCM2 concerns · Avg: 4.0/10
P/E RatioValuation
32.0x4/10

Premium valuation, high expectations priced in

Price/BookValuation
9.4x4/10

Trading at 9.4x book value

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-17.7%2/10

Earnings declined 17.7%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : DXCM

The strongest argument for DXCM centers on Return on Equity, EPS Growth, Operating Margin. Profitability is solid with margins at 17.9% and operating margin at 25.6%. Revenue growth of 13.1% demonstrates continued momentum.

Bull Case : GEHC

The strongest argument for GEHC centers on Return on Equity, P/E Ratio.

Bear Case : DXCM

The primary concerns for DXCM are P/E Ratio, Price/Book.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

DXCM profiles as a mature stock while GEHC is a value play — different risk/reward profiles.

DXCM carries more volatility with a beta of 1.53 — expect wider price swings.

DXCM is growing revenue faster at 13.1% — sustainability is the question.

GEHC generates stronger free cash flow (917M), providing more financial flexibility.

Bottom Line

DXCM scores higher overall (72/100 vs 60/100), backed by strong 17.9% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DexCom Inc

HEALTHCARE · MEDICAL DEVICES · USA

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?